The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
2022 · Leukemia · 3,654 citations
https://doi.org/10.1038/s41375-022-01613-1
U
Uwe Platzbecker
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.5K
Papers
38.1K
Citations
87
h-index
479
i10-index
Uwe Platzbecker is an academic researcher from National Center for Tumor Diseases. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Myeloproliferative Neoplasms: Diagnosis and Treatment & Hematopoietic Stem Cell Transplantation. The author has an h-index of 87, co-authored 1285 publications.
ORCID: 0000-0003-1863-3239Papers by this author
worksImplications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
2020 · Nature Medicine · 618 citations
https://doi.org/10.1038/s41591-020-1008-z
Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry
2016 · Journal of Hematology & Oncology · 180 citations
https://doi.org/10.1186/s13045-016-0242-9
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
2021 · Leukemia · 172 citations
https://doi.org/10.1038/s41375-021-01328-9
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆
2020 · Annals of Oncology · 161 citations
https://doi.org/10.1016/j.annonc.2020.11.002
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
2023 · The Lancet · 154 citations
https://doi.org/10.1016/s0140-6736(23)00874-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat